Hepatitis C Therapy

Phase I trials of Actilon initiated

Published in Hepatitis Weekly, February 9th, 2004

Coley Pharmaceutical Group, Inc., announced the initiation of phase I clinical studies of Actilon (CPG 10101), a novel synthetic TLR9 agonist, targeted for patients with chronic hepatitis C infection (HCV).

Two phase I clinical studies will examine the safety, dose tolerability, immunological and anti-viral activity of subcutaneous Actilon, first in healthy volunteers, and then in HCV positive patients. Coley expects to enroll 40 healthy volunteers and forty patients in these blinded, placebo controlled, dose-escalation studies. The timeline for completing phase I clinical studies of Actilon is the first half of 2004. Information gained in these studies will be used to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-02-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry